Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Stargardt Disease
Interventions: Emixustat, Placebo; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Pemphigus
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more

Conditions: Primary IgA Nephropathy
Interventions: Nefecon, Placebo oral capsule; Drug
Lead sponsor: Asahi Kasei Therapeutics, AB; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more

Conditions: Burn, Pain, Dissociation, Opioid
Interventions: Ketamine, 0.9% NaCl; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV-1 Infection
Interventions: Bictegravir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Berkeley, California • Davis, California • Long Beach, California + 13 more

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Bipolar Disorder
Interventions: Licarbazepine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 16
States / cities: Little Rock, Arkansas • Cerritos, California • San Diego, California + 12 more

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: 10% N2O, 20% N2O, 30% N2O, 40% N2O; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 37 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more

Conditions: NAFLD, NASH
Interventions: Elobixibat, Placebo oral tablet; Drug
Lead sponsor: Albireo; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 10
States / cities: Canoga Park, California • Rialto, California • Colorado Springs, Colorado + 7 more

Conditions: Depression
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Traumatic Brain Injury
Interventions: Cyclosporine (CsA), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Actinic Keratoses
Interventions: Placebo, KX2-391 Ointment 1%; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more

Conditions: Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Interventions: NBI-827104, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Pruritus, Psoriasis
Interventions: SNA-120, Placebo, Calcipotriene; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more

Conditions: Type 1 Hyperlipoproteinemia
Interventions: SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: rosiglitazone, metformin, PN2034; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 21 Years to 72 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more

Conditions: Knee Osteoarthritis
Interventions: Amniotic Suspension Allograft, Placebo; Biological · Drug
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more

Conditions: Menopausal Hot Flashes, Menopausal Women
Interventions: ashwagandha root, ashwagandha root and leaf, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Healthy
Interventions: NRX-1074, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Cutaneous Lupus Erythematosus
Interventions: Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more

Conditions: Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions: V4020; Biological
Lead sponsor: Medigen, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure
Interventions: LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Safety and Efficacy of Emixustat in Stargardt Disease

A Study of PRN1008 in Patients With Pemphigus

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Low-Dose Ketamine Infusion During Burn Wound Care

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

Safety and Efficacy in Adult Subjects With Acute Migraines

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

TRACK-TBI Precision Medicine Part 3 - Option II

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3